Abstract 9P
Background
Previous studies have shown that there is a relationship between high HIF1-α and tumor progression, metastasis and recurrence in solid tumors. However, no study has been conducted on this subject after the use of the anti-VEGF antibody bevacizumab in standard treatment in the treatment of cervical cancer, and we aimed to evaluate the response to platinum-paclitaxel-bevacizumab treatment between patients with high and low HIF1 expression. To our knowledge, this study will be the first study in the literature.
Methods
Our study is a retrospective multicenter study, and patients diagnosed with metastatic cervical cancer and received chemotherapy-bevacizumab were included. The HIF1-α score of the patients was evaluated with the H-score, and patients with a HIF1-α score <100 were considered as HIF1-α low score and patients with a HIF1-α score ≥ 100 were considered as HIF1-α high score. The relationship between HIF1-α expression and median progression-free survival (mPFS) and median overall survival (mOS) was examined.
Results
Thirty-four patients were included in the study. The median age at starting treatment was 57.08 ± 11.65. Nine of the patients had liver metastasis, 11 had lung metastasis, 8 had bone metastasis, and 6 had peritoneal metastasis. While the HIF1-α score of 14 patients was ≥ 100, 20 patients was <100. mPFS in patients with HIF1-α score ≥ 100 was significantly better than in patients with HIF1-α score < 100 (mPFS: 12.90 months (95% CI: 7.59-18.20) vs 4.96 months (95% CI: 3.43-6.50), p=0.011). mOS in patients with HIF1-α score ≥ 100 was significantly better than in patients with HIF1-α score <100 (mPFS: 20.36 months vs 8.30 months; p=0.003).
Conclusions
Previous studies on the effect of HIF1-α level in patients diagnosed with locally advanced cervical cancer have shown that the presence of HIF1-α expression is a negative prognostic factor in patients treated with chemoradiotherapy. In our study, which is the first study in the literature on patients diagnosed with metastatic cervical cancer, we showed that high HIF1-α expression in patients receiving bevacizumab treatment along with standard chemotherapy provided a significant improvement in both PFS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hacettepe University, Ethics Boards and Commissions.
Funding
Turkish Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.